Cargando…
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy at primary cytoreduction of epithelial ovarian cancer based on residual disease status
Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin when used at the time of interval cytoreductive surgery (ICS) after neoadjuvant chemotherapy (NACT) has been shown to provide a survival advantage compared to interval cytoreduction alone for patients with advanced epithelial ovarian c...
Autores principales: | Penn, Courtney A., Carballo, Erica V., Walsh, Christine S., Zivanovic, Oliver, Kim, Kenneth H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149186/ https://www.ncbi.nlm.nih.gov/pubmed/35652061 http://dx.doi.org/10.1016/j.gore.2022.101009 |
Ejemplares similares
-
Cytoreduction with hyperthermic intraperitoneal chemotherapy: An anaesthetic challenge
por: Murughan, Kavita, et al.
Publicado: (2014) -
Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer
por: Tentes, Antonios-Apostolos K., et al.
Publicado: (2012) -
Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer
por: Lei, Ziying, et al.
Publicado: (2020) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
por: Gamboa, Adriana C., et al.
Publicado: (2019) -
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
por: Piso, Pompiliu, et al.
Publicado: (2004)